MLH (Non-CCOP) Cancer Research Studies

Contacts:

Terri Olshefski, Regulatory Coordinator, MLH Cancer Clinical Trials, 484-476-3440

Judith Spahr, Manager, LIMR Clinical Research, 484-476-4625

Study ID	IRB#	Disease	Site	Title
John Wayne Cancer Inst. (MSLT)	2331	Melanoma	L	Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Astra Zeneca	3101	LUNG - Single Patient Only	L	An Open Label Multi-Center, IRESSATM Clinical Access Program of Gefitinib 250mg (IRESSATM) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment
TruBeam	3104	Genitourinary - Prostate (Low or Immediate Risk)	L	Prospective evaluation of Truebeam STX stereotactic body radiosurgery for low and intermediate risk prostate cancer
Marks	3092	Gastrointestinal - Resectable Rectal (Neoadjuvant)	L	Maintenance of chemotherapy following neoadjuvant chemoradiation therapy for distal rectal cancer
FCCC-Survivorship	3308	NSCL/Colorectal	P	Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
ACOSOG Z6051	2741	Gastrointestinal - Resectable Rectal (Neoadjuvant)	L	A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection versus Open Resection for Rectal Cancer